Relationship between soluble MICA and the MICA A5.1 homozygous genotype in patients with oral squamous cell carcinoma

Clinical Immunology

Volumn 130, Issue 3, 2009, Pages 331-337

  Tamaki, Shigehiro ^a   Kawakami, Masayoshi ^a   Yamanaka, Yasutsugu ^a   Shimomura, Hiroyuki ^a   Imai, Yuichiro ^a   Ishida, Jun ichi ^a   Yamamoto, Kazuhiko ^a   Ishitani, Akiko ^a   Hatake, Katsuhiko ^a   Kirita, Tadaaki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Major histocompatibility complex class I chain related gene A (MICA); Natural killer group 2, member D (NKG2D), Microsatellite allele frequencies; Oral squamous cell carcinoma (OSCC)

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RELATED CHAIN A PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOSURVEILLANCE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; SURVIVAL RATE; TUMOR ESCAPE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; POLYMORPHISM, GENETIC; SOLUBILITY;

EID: 59249104966     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.09.004     Document Type: Article

References (38)

1. Klitz W. Viruses, cancer and the MHC. Nature 356 (1992) 17-18
2. Bahram S., Bresnahan M., Geraghty D.E., and Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 6259-6263
3. Groh V., Bahram S., Bauer S., Herman A., Beauchamp M., and Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 12445-12450
4. Bahram S., and Spies T. Nucleotide sequence of a human MHC class I MICB cDNA. Immunogenetics 43 (1996) 230-233
5. Mizuki N., Ota M., Kimura M., Ohno S., Ando H., Katsuyama Y., Yamazaki M., Watanabe K., Goto K., Nakamura S., Bahram S., and Inoko H. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1994) 1298-1303
6. Rueda B., Pascual M., Lopez-Nevot M.A., Gonzale E., and Martin J. A new allele within the transmembrane region of the human MICA gene with seven GCT repeat. Tissue Antigen. 60 (2002) 526-528
7. Gambelunghe G., Brozzetti A.L., Ghaderi M., Tortoioli C., and Falorni A. MICA A8: a new allele within MHC class I chain-related a transmembrane region with eight GCT repeats. Hum. Immunol. 67 (2006)
8. Goto K., Ota M., Ohno S., Mizuki N., Ando H., Katsuyama Y., Maksymowych W.P., Kimura M., Bahram S., and Inoko H. MICA gene and ankylosing spondylitis: linkage analysis via a transmembrane-encoded triplet repeat polymorphism. Tissue Antigens. 49 (1997) 503-507
9. Mok J.W., Lee Y.J., Kim J.Y., Lee E.B., Song T.W., Park M.H., and Park K.S. Association of MICA polymorphism with rheumatoid arthritis patients in Koreans. Hum. Immunol. 64 (2003) 1190-1194
10. Tamaki S., Sanefuzi N., Ohgi K., Imai Y., Kawakami M., Yamamoto K., Ishitani A., Hatake K., and Kirita T. An association between the MICA-A5.1 allele and an increased susceptibility to oral squamous cell carcinomaa in Japanese patients. J. Oral. Pathol. Med. 36 (2007) 351-356
11. Groh V., Kuijl C., Sugita M., Morita C.T., Spies T., and Bukowaki J.F. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15 (2001) 83-93
12. Groh V., Wu J., Steinle A., Phillips J.H., Lanier L.L., and Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
13. Goehlsdorf D., and Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum. Immunol. 67 (2006) 188-195
14. Salih H.R., Antropius H., Gieseke F., Lutz S.Z., Kanz L., Rammensee H.G., and Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102 (2003) 1389-1396
15. Yim D., Chow I.T., Gonzalez S., Dai Z., Mann H.H., Stong R.K., Groh V., and Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447 (2007) 482-486
16. Oppenheim D.E., Steele C.R., Lewis J.M., Glusac E., Filler R., Hobby P., Sutton B., Tigelaar R.E., and Hayday A.C. Regulation of cutaneous malignancy by gammadelta T cells. Science 294 (2001) 605-609
17. Rammensee H.G., and Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. (2002) 4098-4102
18. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
19. Lee K.M., Kim D.W., and Heo D.S. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172 (2004) 7335-7340
20. Prigione I., Airoldi I., Camoriano M., Levreri I., Gambini C., Pende D., Steinle A., Ferrone S., and Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia. 6 (2004) 558-568
21. Wu J.D., Higgins L.M., Steinle A., Cosman D., Haugk K., and Plymate S.R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 114 (2004) 560-568
22. Doubrovina E.S., Doubrovin M.M., Vider E., Sisson R.B., O'Reilly R.J., Dupont B., and Vyas Y.M. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J. Immunol. 171 (2003) 6891-6899
23. Märtin A., von Lilienfeld-Toal M., Büchler M.W., and Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int. J. Cancer 118 (2006) 2359-2365
24. Rebmann V., Schütt P., Brandhorst D., Opalka B., Moritz T., Nowrousian M.R., and Grosse-Wilde H. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin. Immunol. 123 (2007) 114-120
25. Holdenrieder S., Stieber P., Peterfi A., Nagel D., Steinle A., and Salih H.R. Soluble MICA in malignant diseases. Int. J. Cancer 118 (2006) 684-687
26. Xiap P., Xue L., Che L., Yang P., Li Y., and Oiao H. Prevalent expression of MHC class I chain-related molecule A in human osteosarcoma. Neoplasma 55 (2008) 266-272
27. Arreygue-Garcia N.A., Daneri-Navarro A., del Toro-Arreola A., Gonzalez-Ramella O., Delgado-Rizo V., Albarran-Somoza B., Zaitseva G., Flores-Torales E., and del Toro-Arreola S. F.127. Serum levels of MHC class I chain-related molecule (MICA) is augmented in patients with cervical cancer. Clin. Immunol. 119 (2006) 95-96
28. Takezaki T., Hirose K., Inoue M., Hamajima N., Kuroishi T., Nakamura S., Koshikawa T., Matsuura H., and Tajima K. Tobacco, alcohol and dietary factors associated with the risk of oral cancer among Japanese. Jpn. J. Cancer Res. 87 (1996) 555-562
29. Sobin L.H., and Fleming I.D. TNM classification of malignant tumors, fifth edition. Union Internationale Contrele Cancer and the American Joint Committee on Cancer. Cancer 80 (1997) 1803-1804
30. Inoko H., Ando A., Ito M., and Tsuji K. Southern hybridization analysis of DNA polymorphisms in the HLA-D region. Hum. Immunol. 16 (1986) 304-313
31. Tamaki S., Sanefuzi N., Kawakami M., Aoki K., Imai Y., Yamanaka Y., Yamamoto K., Ishitana A., Hatake K., and Kirita T. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum. Immunol. 69 (2008) 88-93
32. Cerwenka H., Baron J.L., and Lanier L.L. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 11521-11526
33. Wu J., Song Y., Bakker A.B., Bauer S., Spies T., Lanier L.L., and Phillips J.H. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285 (1999) 730-732
34. Diefenbach A., Jensen E.R., Jamieson A.M., and Raulet D.H. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001) 165-171
35. Watoson N.F., Spendlove I., Madjd Z., McGilvray R., Green A.R., Ellis I.O., Scholefield J.H., and Durrant L.G. Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 118 (2006) 1445-1452
36. Wischhusen J., Wick W., Weiler M., Eisele G., Steinle A., and Weller M. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64 (2004) 7596-7603
37. Arreygue-Garcia N.A., Daneri-Navarro A., del Toro-Arreola A., Cid-Arregui A., Gonzalez-Ramella O., Jave-Suarez L.F., Aguilar-Lemarroy A., Troyo-Sanroman R., Bravo-Cuellar A., Delgado-Rizo V., Garcia-Iqlesias T., Hernandez-Flores G., and Del Toro-Arreola S. Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer 21 (2008) 8-16
38. Ciacci C., Calcagno G., Gennarelli D., Spampanato A., farinaro E., Tortora R., and Sacchetti L. Increased prevalence of celiac disease without gastrointestinal symptoms in adults MICA 5.1 homozygous subjects from the Campania area. Dig. Liver Dis. 40 (2008) 248-252